Florida Nurse Practitioner Barred from Handling Controlled Substances Over Exclusion
Published Date: 1/15/2026
Notice
Summary
Honorata Anna Itaman, a nurse practitioner from Florida, tried to get a DEA registration but was denied because she’s excluded from Medicare and other federal health programs. She didn’t ask for a hearing, so the denial stands. This means she can’t legally handle controlled substances, affecting her work and income starting now.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
DEA Registration Denied for Itaman
The Drug Enforcement Administration denied Honorata Anna Itaman's application for a DEA Certificate of Registration (Control No. W24026383M). The Order is effective February 17, 2026, and the denial means she cannot hold a DEA registration and therefore cannot legally possess or handle controlled substances, which affects her ability to work and earn income.
Exclusion Blocks DEA Registration
The DEA may deny an application for registration when an applicant has been excluded from Medicare, Medicaid, or all federal health care programs under 42 U.S.C. 1320a-7(a). In this case, HHS/OIG mandatorily excluded the applicant effective September 19, 2024 for a period of 11 years, and the DEA relied on that exclusion as a statutory basis to deny the registration.
Default for No Hearing Request
If an applicant does not file a written request for a hearing in response to an Order to Show Cause, the applicant is deemed in default and is treated as admitting the factual allegations, which can lead to a final denial. The record shows the applicant did not request a hearing and was therefore deemed in default, leading to denial.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20535, Arenbii Pharmacy LLC; Decision and Order
Arenbii Pharmacy in Texas lost its DEA license because it kept filling risky drug prescriptions without fixing obvious problems. This means they can’t legally handle certain controlled medicines anymore, protecting public safety. The decision is final, and Arenbii didn’t ask for a hearing, so the revocation starts now with no chance to appeal.
2026-20553, Decision and Order: Medpharm Research, LLC
Medpharm Research, LLC wanted to get official permission to make marijuana in bulk, but the DEA said no. The DEA found that Medpharm’s related companies were handling marijuana without permission and even selling it for recreational use, which breaks the rules. So, Medpharm’s application was denied, and they can’t legally manufacture marijuana in bulk now.
Previous / Next Documents
Previous: 2026-00622, Proviso Railroad, Inc.-Acquisition Exemption-L. Neill Cartage Co., Inc.
Proviso Railroad, Inc. is set to take over and operate a short rail line owned by L. Neill Cartage Co. in Berkeley, Illinois, used for moving goods like paper and lumber. This change kicks in on January 29, 2026, with no big money shifts expected since Proviso’s revenue stays small. The move keeps future rail connections open and promises smooth cargo swaps with Union Pacific Railroad.
Next: 2026-00624, Mason Railroad, Inc.-Acquisition Exemption-L. Neill Cartage Co., Inc.
Mason Railroad, Inc. is set to take over and operate a short rail line owned by L. Neill Cartage Co. in Bedford Park, Illinois, starting January 29, 2026. This line helps move bulk goods like paper and lumber by connecting with a bigger railway. The deal won’t change future rail connections and won’t bring big money changes, keeping things smooth and local.